- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- TORRENT PHARMACEUTICALS LIMITED (pharmaceuticals)
- TORRENT PHARMACEUTICALS LIMITED Financial Data
Torrent Pharma Fact Sheet 
(TORR)
Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
TORRENT PHARMA Price History
| % ch | % | 0.3 |
| No. of shares | m | 169.26 |
| % ch week | % | -0.9 |
| % ch 1-mth | % | -6.1 |
| % ch 12-mth | % | 25.3 |
| 52 week H/L | Rs | 1,960.0/1,223.8 |
TORRENT PHARMA Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| TORRENT PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 578 | 1,232 | 1,720 | 1,768 | 1,550 | |
| Low | Rs | 334 | 523 | 1,134 | 1,186 | 1,144 | |
| Sales per share (Unadj.) | Rs | 247.3 | 275.0 | 394.5 | 346.1 | 354.7 | |
| Earnings per share (Unadj.) | Rs | 39.2 | 44.4 | 102.4 | 55.2 | 40.1 | |
| Diluted earnings per share | Rs | 39.2 | 44.4 | 102.4 | 55.2 | 40.1 | |
| Cash flow per share (Unadj.) | Rs | 44.4 | 55.6 | 116.5 | 73.3 | 64.2 | |
| Dividends per share (Unadj.) | Rs | 10.00 | 11.25 | 40.00 | 14.00 | 14.00 | |
| Adj. dividends per share | Rs | 10.00 | 11.25 | 39.99 | 14.00 | 14.00 | |
| Dividend yield (eoy) | % | 2.2 | 1.3 | 2.8 | 0.9 | 1.0 | |
| Book value per share (Unadj.) | Rs | 112.4 | 156.2 | 206.5 | 257.1 | 273.1 | |
| Adj. book value per share | Rs | 112.4 | 156.1 | 206.4 | 257.0 | 273.1 | |
| Shares outstanding (eoy) | m | 169.22 | 169.22 | 169.22 | 169.22 | 169.22 | |
| Bonus/Rights/Conversions | B1:1 | - | - | - | - | ||
| Price / Sales ratio | x | 1.8 | 3.2 | 3.6 | 4.3 | 3.8 | |
| Avg P/E ratio | x | 11.6 | 19.8 | 13.9 | 26.8 | 33.6 | |
| P/CF ratio (eoy) | x | 10.3 | 15.8 | 12.3 | 20.1 | 21.0 | |
| Price / Book Value ratio | x | 4.1 | 5.6 | 6.9 | 5.7 | 4.9 | |
| Dividend payout | % | 25.5 | 25.4 | 39.1 | 25.4 | 34.9 | |
| Avg Mkt Cap | Rs m | 77,190 | 148,465 | 241,435 | 249,887 | 227,897 | |
| No. of employees | `000 | 9.5 | 11.0 | 10.9 | 11.8 | 14.7 | |
| Total wages/salary | Rs m | 7,411 | 8,418 | 8,424 | 9,934 | 11,353 | |
| Avg. sales/employee | Rs Th | 4,386.5 | 4,212.4 | 6,129.6 | 4,971.5 | 4,083.0 | |
| Avg. wages/employee | Rs Th | 776.8 | 762.0 | 773.4 | 843.2 | 772.3 | |
| Avg. net profit/employee | Rs Th | 695.9 | 679.8 | 1,591.3 | 792.4 | 461.3 | |
| TORRENT PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 41,847 | 46,535 | 66,764 | 58,569 | 60,021 | |
| Other income | Rs m | 381 | 2,856 | 2,256 | 2,233 | 2,988 | |
| Total revenues | Rs m | 42,229 | 49,390 | 69,020 | 60,802 | 63,009 | |
| Gross profit | Rs m | 9,515 | 10,202 | 27,330 | 13,773 | 13,493 | |
| Depreciation | Rs m | 870 | 1,907 | 2,376 | 3,069 | 4,086 | |
| Interest | Rs m | 586 | 1,752 | 1,840 | 2,056 | 3,085 | |
| Profit before tax | Rs m | 8,440 | 9,398 | 25,371 | 10,881 | 9,310 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | -1,936 | 0 | 0 | |
| Tax | Rs m | 1,801 | 1,888 | 6,102 | 1,545 | 2,529 | |
| Profit after tax | Rs m | 6,639 | 7,509 | 17,333 | 9,336 | 6,781 | |
| Gross profit margin | % | 22.7 | 21.9 | 40.9 | 23.5 | 22.5 | |
| Effective tax rate | % | 21.3 | 20.1 | 24.1 | 14.2 | 27.2 | |
| Net profit margin | % | 15.9 | 16.1 | 26.0 | 15.9 | 11.3 | |
| TORRENT PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 34,045 | 40,983 | 46,882 | 48,794 | 52,623 | |
| Current liabilities | Rs m | 21,746 | 27,046 | 32,855 | 27,383 | 52,022 | |
| Net working cap to sales | % | 29.4 | 30.0 | 21.0 | 36.6 | 1.0 | |
| Current ratio | x | 1.6 | 1.5 | 1.4 | 1.8 | 1.0 | |
| Inventory Days | Days | 88 | 84 | 74 | 97 | 120 | |
| Debtors Days | Days | 96 | 125 | 79 | 59 | 76 | |
| Net fixed assets | Rs m | 14,095 | 34,720 | 39,007 | 42,079 | 85,016 | |
| Share capital | Rs m | 846 | 846 | 846 | 846 | 846 | |
| "Free" reserves | Rs m | 17,272 | 25,583 | 34,095 | 42,655 | 45,376 | |
| Net worth | Rs m | 19,024 | 26,430 | 34,941 | 43,501 | 46,222 | |
| Long term debt | Rs m | 7,445 | 21,729 | 18,501 | 22,408 | 41,115 | |
| Total assets | Rs m | 50,698 | 79,641 | 90,579 | 97,021 | 142,432 | |
| Interest coverage | x | 15.4 | 6.4 | 14.8 | 6.3 | 4.0 | |
| Debt to equity ratio | x | 0.4 | 0.8 | 0.5 | 0.5 | 0.9 | |
| Sales to assets ratio | x | 0.8 | 0.6 | 0.7 | 0.6 | 0.4 | |
| Return on assets | % | 14.3 | 11.6 | 21.2 | 11.7 | 6.9 | |
| Return on equity | % | 34.9 | 28.4 | 49.6 | 21.5 | 14.7 | |
| Return on capital | % | 34.1 | 23.2 | 47.3 | 19.6 | 14.2 | |
| Exports to sales | % | 37.4 | 30.4 | 43.3 | 0 | 0 | |
| Imports to sales | % | 8.2 | 6.0 | 6.9 | 0 | 0 | |
| Exports (fob) | Rs m | 15,665 | 14,136 | 28,934 | 0 | 0 | |
| Imports (cif) | Rs m | 3,416 | 2,801 | 4,584 | 0 | 0 | |
| Fx inflow | Rs m | 16,862 | 14,265 | 29,185 | 20,066 | 14,580 | |
| Fx outflow | Rs m | 5,196 | 5,184 | 6,021 | 5,304 | 3,600 | |
| Net fx | Rs m | 11,666 | 9,081 | 23,165 | 14,762 | 10,980 | |
| TORRENT PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 5,994 | 8,102 | 27,421 | 10,088 | 8,942 | |
| From Investments | Rs m | -3,558 | -21,623 | -8,379 | -7,869 | -47,070 | |
| From Financial Activity | Rs m | 864 | 12,123 | -14,352 | -1,929 | 34,174 | |
| Net Cashflow | Rs m | 3,300 | -1,399 | 4,375 | 177 | -3,655 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Sudhir Mehta | COMP SEC: Mahesh Agarwal | YEAR OF INC: 1973 | BSE CODE: 500420 | FV (Rs): 5 | DIV YIELD (%): 0.8 |
More Pharmaceuticals Company Fact Sheets: VENUS REMEDIES SUN PHARMA NATCO PHARMA ALEMBIC LTD STRIDES PHARMA SCIENCE
Compare TORRENT PHARMA With: VENUS REMEDIES SUN PHARMA NATCO PHARMA ALEMBIC LTD STRIDES PHARMA SCIENCE
Compare TORRENT PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Where Will the Two-Faced Market Go from Here?(Podcast)
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
Views on news
TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)
Jan 31, 2019 | Updated on Jan 31, 2019For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
Feb 4, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)
Feb 5, 2019A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)
Feb 5, 2019While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More|
| |
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA - J.B.CHEMICALS COMPARISON
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.